Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.

Q3 Medicine
Exploration of targeted anti-tumor therapy Pub Date : 2025-02-24 eCollection Date: 2025-01-01 DOI:10.37349/etat.2025.1002294
Narimene Beder, Seyedeh Nasim Mirbahari, Mourad Belkhelfa, Hamid Mahdizadeh, Mehdi Totonchi
{"title":"Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.","authors":"Narimene Beder, Seyedeh Nasim Mirbahari, Mourad Belkhelfa, Hamid Mahdizadeh, Mehdi Totonchi","doi":"10.37349/etat.2025.1002294","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion. This review highlights oncolytic virotherapy as a promising therapeutic avenue, focusing on its potential to modulate neuroinflammatory responses, induce localized immune reactions, and deliver immunomodulatory factors directly to the tumor site. While encouraging outcomes have been observed, challenges such as overcoming the blood-brain barrier, managing host antiviral immunity, and mitigating potential risks to normal neuronal cells remain critical barriers to clinical translation. By analyzing the intricate interactions of oncolytic viruses with the glioblastoma microenvironment and synthesizing findings from preclinical and clinical trials, this review provides actionable insights into developing personalized and effective therapeutic strategies for this aggressive tumor based on oncolytic virotherapy alone or when using it combined with conventional therapies, immunotherapy, natural killer-cell therapy, chimeric antigen receptor-T cell therapy, and dendritic cell therapy.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":"6 ","pages":"1002294"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886384/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploration of targeted anti-tumor therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37349/etat.2025.1002294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion. This review highlights oncolytic virotherapy as a promising therapeutic avenue, focusing on its potential to modulate neuroinflammatory responses, induce localized immune reactions, and deliver immunomodulatory factors directly to the tumor site. While encouraging outcomes have been observed, challenges such as overcoming the blood-brain barrier, managing host antiviral immunity, and mitigating potential risks to normal neuronal cells remain critical barriers to clinical translation. By analyzing the intricate interactions of oncolytic viruses with the glioblastoma microenvironment and synthesizing findings from preclinical and clinical trials, this review provides actionable insights into developing personalized and effective therapeutic strategies for this aggressive tumor based on oncolytic virotherapy alone or when using it combined with conventional therapies, immunotherapy, natural killer-cell therapy, chimeric antigen receptor-T cell therapy, and dendritic cell therapy.

揭示潜能:溶瘤病毒在胶质母细胞瘤中的神经炎症调节机制。
胶质母细胞瘤是一种侵袭性和致死性的脑肿瘤,具有巨大的临床挑战,包括分子异质性、高复发率、对常规治疗的耐药性以及治疗穿透血脑屏障的能力有限。胶质母细胞瘤微环境以细胞和非细胞成分的动态相互作用为特征,是肿瘤生长和治疗耐药性的关键驱动因素。神经炎症细胞因子,特别是白细胞介素和肿瘤坏死因子- α,在这种微环境中发挥关键作用,促进肿瘤进展和免疫逃避。这篇综述强调了溶瘤病毒疗法作为一种有前途的治疗途径,重点是其调节神经炎症反应、诱导局部免疫反应和将免疫调节因子直接传递到肿瘤部位的潜力。虽然已经观察到令人鼓舞的结果,但克服血脑屏障、管理宿主抗病毒免疫和减轻对正常神经元细胞的潜在风险等挑战仍然是临床转化的关键障碍。通过分析溶瘤病毒与胶质母细胞瘤微环境的复杂相互作用,并综合临床前和临床试验的结果,本综述为针对这种侵袭性肿瘤开发个性化和有效的治疗策略提供了可行的见解,这些策略是基于单独溶瘤病毒治疗或与常规疗法、免疫疗法、自然杀伤细胞疗法、嵌合抗原受体- t细胞疗法、树突细胞疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信